Global Intermittent Claudication Market Size By Type (Medication Therapies, Revascularization), By Application (Hospitals, Clinics), By Region, And Segment Forecasts, 2023 to 2032

The Global Intermittent Claudication Market was valued at USD 2.3 billion in 2023 and is projected to reach USD 4.1 billion by 2031, expanding at a CAGR of 7.2% during the forecast period from 2023 to 2031. Intermittent claudication, a symptom of peripheral artery disease (PAD), is gaining clinical attention due to its increasing prevalence among the aging population and individuals with cardiovascular risk factors like diabetes, hypertension, and smoking. Market growth is driven by advancements in diagnostic imaging, the rise in minimally invasive therapies, and growing patient awareness coupled with improved healthcare infrastructure in emerging economies.

Drivers:

1. Growing Prevalence of Peripheral Artery Disease (PAD):

The rising incidence of PAD globally, particularly in elderly and diabetic populations, is directly influencing the demand for therapies targeting intermittent claudication.

2. Advances in Endovascular Treatment:

New technologies such as drug-eluting stents, atherectomy devices, and image-guided procedures are making treatments less invasive and more effective, thereby accelerating adoption.

3. Increasing Healthcare Access and Screening:

Expanding healthcare access in developing regions and rising awareness initiatives from health organizations are contributing to early diagnosis and treatment uptake.

Restraints:

1. High Cost of Advanced Treatments:

While minimally invasive interventions are effective, their high costs may deter adoption in low-income settings or where health insurance coverage is limited.

2. Lack of Awareness in Early-Stage PAD:

Intermittent claudication is often underdiagnosed due to misinterpretation of symptoms or lack of early-stage awareness, potentially delaying timely treatment.

Opportunity:

1. Market Penetration in Emerging Economies:

Growing investment in healthcare infrastructure and patient outreach in Asia-Pacific and Latin America presents significant market expansion opportunities.

2. Integration of AI in Vascular Imaging and Diagnostics:

The integration of artificial intelligence and machine learning in imaging is enabling earlier and more accurate detection of PAD, fostering timely management of intermittent claudication.

Market by System Type Insights:

Based on system type, the Pharmacological Therapy segment dominated the market in 2023 due to the widespread use of vasodilators, antiplatelet agents, and statins in first-line management. However, the Endovascular Therapy segment is expected to grow rapidly over the forecast period, owing to patient preference for less invasive procedures, shorter hospital stays, and enhanced clinical outcomes.

Market by End-use Insights:

The Hospitals and Specialty Clinics segment accounted for the largest share in 2023, driven by the availability of advanced imaging technologies and skilled vascular specialists. The Outpatient Centers segment is projected to exhibit the highest growth rate, supported by the shift toward ambulatory care and cost-effective intervention models.

Market by Regional Insights:

North America led the global market in 2023, attributed to its established healthcare infrastructure, high disease prevalence, and strong reimbursement policies. Meanwhile, Asia-Pacific is forecasted to experience the fastest growth, driven by rising elderly populations, improving diagnostic access, and increased government spending on chronic disease management.

Competitive Scenario:

Key players in the Global Intermittent Claudication Market include Abbott Laboratories, Medtronic plc, Boston Scientific Corporation, Cook Medical, Becton, Dickinson and Company, Cardinal Health, Philips Healthcare, Terumo Corporation, and AngioDynamics. These companies are actively focusing on innovations in stent technologies, pharmacological pipelines, and strategic collaborations to enhance their market footprint.

Key Market Developments:

2023: Abbott Laboratories launched a next-generation drug-coated balloon catheter specifically for PAD treatment in Europe and North America.

2024: Boston Scientific introduced a novel atherectomy system that combines laser therapy with imaging-guided delivery.

2025: Terumo Corporation expanded its endovascular device manufacturing capabilities in Asia to meet growing demand.

Scope of Work – Global Intermittent Claudication Market

Report Metric Details

Market Size (2023) USD 2.3 billion

Projected Market Size (2031) USD 4.1 billion

CAGR (2023–2031) 7.2%

Market Segments By System Type (Pharmacological Therapy, Endovascular Therapy), By End-use (Hospitals & Specialty Clinics, Outpatient Centers), By Region

Growth Drivers Growing prevalence of PAD, Advancements in minimally invasive treatments, Increasing screening and diagnosis

Opportunities Emerging healthcare markets, Integration of AI in diagnostics

FAQs:

1) What is the current market size of the Global Intermittent Claudication Market?

The market was valued at USD 2.3 billion in 2023.

2) What is the major growth driver of the Global Intermittent Claudication Market?

The key driver is the rising prevalence of peripheral artery disease and the adoption of minimally invasive treatments.

3) Which is the largest region during the forecast period in the Global Intermittent Claudication Market?

North America is expected to dominate due to advanced healthcare systems and strong diagnostic capabilities.

4) Which segment accounted for the largest market share in the Global Intermittent Claudication Market?

The Pharmacological Therapy segment accounted for the largest market share in 2023.

5) Who are the key market players in the Global Intermittent Claudication Market?

Key players include Abbott Laboratories, Medtronic plc, Boston Scientific Corporation, Cook Medical, and Terumo Corporation.

Would you like a visual infographic or chart to support this report?